PHP78 Assessing The Efficiency Of The Long-Term Care Hospital Units In Hungary Between 2006 And 2013  by Csákvári, T et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  A527
burse different essential medicine causing inequity to access essential medicines. 
Federal ministry of health tried to unify essential list in 10 different cantons by 
Order from 2011 but this has never been fully implemented by all 10 cantonal HIFs. 
In Republic of Srpska (RS) there is one HIF, and 3rd administrative part Brcko District 
(BD) has its own HIF. Methods: We compered average reimbursed prices from 
main HIFs in B&H for most commonly proscribed primary care medicines based 
on 2014 Annual report on medicines utilization issued by Agency for medicines of 
B&H. Average prices have been taken into account since different presentation of 
the same INN (dosage and number of units in pack) are reimbursed. All prices are 
expressed in EUR and represents prices paid by HIF. Results: Comparing Federal 
MoH proposed reimbursed prices and prices from RS HIF s it is noted that prices are 
higher in RS (+20% on average) except in case of bisoprolol. The highest difference is 
for atorvastatin (+39%). Prices in BD are on average lover for -14% vs Federal prices 
and -43% vs RSHIF prices. There are high differences among cantonal RB prices 
comparing to Federal proposal and among main 3 cantons. Atorvastatin is not reim-
bursed in Tuzla and Zenica Canton, while rosuvastatin is not reimbursed in Tuzla 
Canton and BD. Also different copayment levels are introduced at cantonal HIF level 
causing additional inequalities. ConClusions: Different prices cause inequity to 
access essential medicines for inhabitants living in different administrative regions. 
It also impact market indifferences. Implementation of unified and centralized 
pricing system would positively impact on access to medicines and HIFs spending.
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objeCtives: Generally, socioeconomic conditions can be recognised as core determi-
nants of health status. The aim of this study is to identify how the sociodemographic 
characteristics of the population influence self-rated health (SRH) as well as to exam-
ine the relationship between SRH and subjective social status (SSS). Methods: A 
cross-sectional survey was conducted on a representative national sample of 2012 
adult individuals. Respondents were asked to self-evaluate their social status on a 
10-step ladder-based survey tool where 10 represented the highest subjective social 
stratum. Data were analyzed through an ordinal logistic regression model to identify 
the unique characteristics that exist between SRH, sociodemographic characteristics 
and SSS. Results: Older individuals and chronic patients had a lower probability of 
rating their health high. Odds ratio for older age was 0.74 and for the non existence 
of a chronic disease was 4.30. A relation between social interactions and health levels 
was documented. This can be interpreted by the positive relation (OR= 1.27) between 
SRH and social support, where individuals who reported having more people to rely 
on had a higher probability to self-rate their health higher. In terms of the SSS, there 
is a significant statistical positive association (OR= 1.24) with SRH. It is worth adding 
that the highest percentage of respondents (27.4%) rated their SSS as moderate (step 
5), while 69.5% of the respondents reported a positive health level. ConClusions: 
This study provides evidence on the association between socioeconomic factors and 
SRH among the Greek adult population. This contributes to the understanding of the 
complex inter-relationships leading to health inequalities in societies with prevalent 
socioeconomic disparities. Since Greece is going through a deep economic recession, 
such rising inequalities are observed.
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objeCtives: Evidence based medicine has been used for about two decades as meth-
odology for obtaining, evaluating and presenting information on health related topics. 
The present study investigated the question of the appearance of the ideas of evi-
dence based medicine in documents describing the functioning of health care sys-
tems in countries not belonging to the European Union. Methods: The documents 
available in the European Observatory on Health Systems and Policies database were 
considered to reliable represent the health system of non-European Union countries 
too. Electronic search was carried out, each ‘evidence’ expression was categorised 
afterwards into different topics. Deadline of the search was March, 2015. Results: 
The cumulative length of the documents was 4680 pages; there was no document 
without mentioning the idea of evidence based medicine. Among the altogether 431 
mentionings of evidence based medicine, we were able to categorise 295 representa-
tions of the idea into one of the following 4 topics: 1. resources of health care, 2. health 
technology assessment, 3. organisation of health care and 4. environment of health 
care within the society. Evidence based medicine was mentioned 49 times in connec-
tion with the resources of health care, whereas 20 mentionings were related to health 
technology assessment. Organisation of health care was mentioned together with evi-
dence based medicine at 152 occasions, whereas the idea of evidence based medicine 
was related to the social environment of health care in 74 instances. ConClusions: 
The results of the present data collection indicate that the methodology of evidence 
based medicine has already been widely used within the documents describing health 
systems and policies also in countries not belonging to the European Union.
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objeCtives: There was a significant regulation of the inpatient care hospital 
capacity in the last decade in Hungary. The ratio of short- and long term care hos-
population has lost its job and in many cases the insurance capacity.The objective 
of this study was to identify the problems related with the access to health care 
services of Greek and immigrants who visitednon-governmental clinics in Athens, 
in order to receive free of charge health services. The inclusion criteria for participa-
tion in the study was the satisfactory level of understanding the Greek language, 
the lack of insurance or employment or alternatively being under the risk of pov-
erty. Methods: A cross-sectional study was conducted. The study population con-
sisted of 100 people, Greek and migrants, living in Athens. The participants were> 18 
years. The research team developed a questionnaire that included information about 
sociodemographic characteristics, health status, public healthservices knowledge 
and utilization and difficulties in health services access. The questionnaire was 
completed through interviews. Data analysis was performed with the IBM SPSS 
19.0 (Statistical Package for Social Sciences). Results: The lack of knowledge about 
programs which may provide access to health care services was among the most 
significant findings. More than 90% of the respondents reported that they were not 
informed about the legal arrangements voted recently for the universal coverage of 
uninsured population. Other significant barriers in accessing health care services 
included cost as 92, 1% of the respondents stated that they couldn’t afford to buy 
the recommended treatment and the bureaucratic procedures. ConClusions: 
The last law amendments ensuring accessibility of vulnerable groups to health 
services are definitely towards the right direction. Yet, it is important that equal 
access should be re-established along with the provision of integrated, qualitative 
and undifferentiated care.
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objeCtives: Economic evaluation is well regarded by policymakers as a tool 
for healthcare priority setting, but is often not used in practice. We explored the 
perspectives of both users (stakeholders) and producers (health economists) of 
economic evaluations to understand the underutilisation of economic evidence 
in healthcare decision making. Methods: A mixed methods approach was 
used. Stakeholders (health professionals, healthcare administrators or managers, 
and health researchers) were surveyed regarding to understand the factors that 
determine whether they use evidence from economic evaluations. The relative 
importance of these factors was measured using a discrete choice experiment. 
Perspectives of health economists were gathered through semi-structured inter-
views. Results: The survey was answered by 93 stakeholders. Important factors 
to stakeholders included quality of clinical evidence, quality of economic evidence, 
timeliness, applicability, communication and conflicts of interest. Ten health econo-
mists participated in semi-structured interviews. They discussed methods they 
used to translate their research into healthcare practice. Topics discussed included 
the nature of stakholder engagement and how the production of of economic evi-
dence was tailored to meet specific contextual needs. It was generally considered 
best when stakeholder engagement begins early and is maintained throughout the 
research process. ConClusions: These findings are being used to inform recom-
mendations for translating evidence from economic evaluation into clinical practice. 
Such recommendations need to balance stakeholder needs with the constraints 
that health economists face.
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objeCtives: In order to launch a reimbursed drug in France, products with mar-
keting authorization (MA) are firstly assessed by the Transparency Committee (CT, 
Commission de la Transparence) and then undergo pricing negotiations with the 
Pricing Committee (CEPS, Comité Economique des Produits de Santé). This process 
has an impact on time to market launch (ML). The Temporary Authorization for 
Use (ATU) allows early access of drugs to patients before MA and could reduce 
time to ML. Our aim was to compare the time from MA to ML between ATU and 
non-ATU drugs. Methods: Using the Prismaccess database, research was carried 
out to identify ATU and non-ATU drugs to calculate their time to ML from January 
2013 to June 2015. Mean total time (MA-ML) and mean intermediate times (MA-CT 
opinion and CT opinion-ML) were compared between groups using Mann-Whitney 
test (α = 0.05). Results: French health authorities assessed 7 ATU and 18 non-ATU 
drugs during the reviewed period. The mean total time (MA-ML) was shorter for ATU 
drugs compared to non-ATU drugs (281±58 versus 493±245 days; p= 0.017). Similarly, 
the mean time from MA to CT opinion was shorter for ATU drugs compared to 
non-ATU drugs (141 ± 39 versus 489 ± 727 days; p= 0.004). In contrast, no difference 
was reported in time from CT opinion to ML (143 ± 43 versus 166 ± 101 days; p > 
0.05). ConClusions: Overall, ATU drugs seem to launch faster with respect to the 
total time from MA to ML which is mainly due to the reduced time from MA to CT 
opinion. Indeed, the specific regulatory framework for ATU drugs requires pharma-
ceutical companies to submit a CT dossier within one month of MA. Nevertheless, 
the pricing negotiation process, i.e. time from CT opinion to ML, does not change 
between ATU and non-ATU drugs.
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diffeRences in ReimBuRsemenT PRices and inequaliTies To access 
mosT commonly PRescRiBed medicines in Bosnia and HeRzeGovina
Catic T
ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia
objeCtives: Bosnia and Herzegovina have highly decentralized healthcare system 
which is financed by 12 different health insurance funds (HIF) based on administra-
tive organization of the country. Depending on budget ability different HIFs reim-
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objeCtives: Drug development is an expensive process, partly because of the 
required testing for human toxicity and efficacy of drugs. Organ-on-a-chip is a 
multichannel 3D microfluidic cell culture chip that simulates the activities and 
mechanics of entire organs and organ systems. Organ-on-chip is expected to 
reduce the amount of animal testing, and may increase efficiency of drug devel-
opment. For instance, when organ-on-a-chip is used to replace or add to in vivo 
testing experiments, 7.5-10% of drug development costs may be saved. This study 
explores the expected advantages of organ-on-chip technologies as well as poten-
tial barriers to implement. Methods: Stakeholders (n= 50) in this research were 
employees of pharmaceutical companies (n= 18, 36%), developers of microfluidic 
systems and university employees affiliated with organ-on-a-chip/ microfluidic 
systems development and/or drug development (n= 22, 44%). Stakeholders were 
asked their expert opinions about the potential benefits of organ-on-chip using a 
survey (LimeSurvey), which was based on information previously acquired from 
expert interviews. Results: According to stakeholders, organ-on-a-chip may be 
most promising in basic research stage (90%) or the preclinical stage (88%) of drug 
development. Simple models can be used for target identification (70%) while com-
plex models could lead to replacement of animals (78%). However, head-to-head 
studies are needed to change regulations, leaving organ-on-a-chip as an add-on in 
drug development for now. There are significant differences between stakeholders 
opinions about advantages. Most promising organ-on-chip developments should 
target organs like Liver (20%), heart (18%) and kidney (17%). ConClusions: Organ-
on-a-chip can be a valuable add-on in the drug development process, in particular in 
basic research or preclinical stage of the drug development process. Given the very 
early stage of organ-on-chip technologies, it is hard to predict return on investment.
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objeCtives: Understand how medical and pharmacy directors (MDs+PDs) and 
pharmacy and therapeutics (P&T) committees from public and private health 
plans, insurers, and PBMs administer formularies, make formulary decisions today, 
and expected changes for the future. Methods: Online interactive survey of US 
MDs+PDs. Results: Fifty-four percent of respondents were MDs, the remainder 
mostly pharmacists. Most worked for a health plan (83.6%) and 39.6% of the plans 
were local; 35.4% national; and 25.0% regional and 86% were involved in formulary 
decisions. AMCP-dossiers are: not-required (52.2%), used for back-ups (39.1%) and 
used as a basis for reviews (8.9%). Clinician-administered products (ex. office admin-
istered injections) are always under the medical-benefit (67.3%), no plans exclusively 
under the pharmacy-benefit, the remaining 32.7% determine the benefit using cost-
thresholds; most plans (72.9%) do not anticipate a change, 18.8% expect a change 
before 12-2016, 2.1% before 12-2018. Mental health (MH) products were carved-out 
in 1/3 of plans, conditions with multiple MH therapies required generics first (45%), 
mandatory step-therapy (37.5%) and require care by a psychiatrist (17.5%). Most 
were happy with their pharmacy-benefit design, the most requested changes were 
more restrictive management programs; followed by changes in tiers/co-pays. Most 
respondent didn’t desire a change to their P&T process; desired changes included 
more frequent meetings/time; and the use of Comparative Effectiveness Research. 
Most advisors happy with their plan’s medical-benefit management, the most 
desired changes included integration of benefits/departments and more restrictive 
networks. Top current medical concerns: Cancer/oncology, Diabetes and Hepatitis-C. 
Top current budget concerns Hepatitis-C, Cancer/oncology, and Diabetes. Future 
areas of concern include biosimilars, immunomodulators, cardiovascular/heart dis-
ease; multiple sclerosis; biologics; orphan/rare diseases. ConClusions: Managed 
care uses a variety to tools for formulary managment, including benefit type, man-
datory generics and step-therapy. Understanding how decisions are made today 
and concerns for today and in the future can help guide product development.
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objeCtives: Pharmacy Information System (PIS) in hospital pharmacies can opti-
mize the institutional Pharmacy Benefit Management Program (PBMP) and patients’ 
outcomes if the PIS has high detection and reporting capabilities. The aim of the 
study is to explore and investigate the PIS capabilities in tertiary and secondary 
hospitals in Riyadh city, Saudi Arabia. Methods: A cross-sectional survey tar-
geted pharmacy mangers in hospital with inpatient and outpatient pharmacies 
in Riyadh City in 2014. The survey gathered information about PIS characteristics 
such as detection capabilities (drug interactions, drug allergy, etc.), drug utilization 
reporting capabilities, and PIS integration with Electronic Medical Record (EMR) 
Computerized Physician Ordered Entry (CPOE). Results: Of 30 hospital pharmacies, 
23 (76.6%) pharmacy managers responded, only 21(70%) hospital pharmacies met 
the inclusion criteria, 15 (71.4%) are governmental and 6 (28.6%) are private hospi-
tals, 18(85.7% ) hospitals have EMR, 19 (90.5%) hospital pharmacies have PIS. Of the 
14(66.67%) hospitals with CPOE, only 9 (64.2%) have CPOE that are integrated with 
inpatient and outpatient PIS. For the PIS capabilities, out of the 21 hospitals; 8 (38.1%) 
were able to detect incorrect dose and duration, 7 (33.3%) for drug-drug interaction, 
5(23.8%) for drug-disease Interaction, 6 (28.6%) for contraindication, 6(28.6%) for the 
pital beds changed significantly in 2007 and 2011. The aim of our study is to assess 
the efficiency of the long-term care system in Hungary, to examine the effect of 
these regulations. Methods: We used input-oriented Data Envelopment Analysis 
to calculate technical- and scale efficiency. We chose five variables: number of 
beds, average length of stay (inputs), number of discharged patients, amount of 
fee paid by the NHIF, and the number of days (outputs). We examined years 2006 
(N= 109), 2010 (N= 121) and 2013 (N= 111). Units operating with less than 50 bed 
were excluded. Data were collected from databases of the Hungarian National 
Health Insurance Fund. For our calculations we used the DEAP 2.1. Results: In 
these years all of the selected variables were increasing, except the average length 
of stay. Technical efficiency was 94.2% in 2006, 88.6% in 2010 and 95.1% in 2013. 
Scale efficiency was 91.4% in 2006, 90.9% in 2010, 92.7% in 2013. Ratio of technically 
efficient units: 24.8% of units were fully efficient in 2006 (n= 27), 19.8% (n= 24) in 
2010, and 35.1% (n= 39) in 2013. The ratio of units achieved 100% scale efficiency 
was 12.8% (n= 14), 5.8% (n= 7) and 17.1% (n= 19). Almost all units were “increasing 
return to scale”, which means they could increase their level of efficiency, if they 
had larger size (more beds). ConClusions: Based on the results we can say 
that the units have relatively high values in all years. Efficiency scores decreased 
slightly in 2006-2010, but showed improvement in the next three years. We can 
conclude that the Hungarian long-term care needs to reduce the number of units, 
but needs to improve the size of them.
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objeCtives: Since 2009, Chinese government has constructed essential medicines 
policy of centralized purchasing, uniform distribution, compulsory use and “zero-
mark-up” (i.e. no-profit) sale for essential medicines in primary care, but the policy 
does not regulate the drugstore. As a result, competition relationship between 
drugstore and primary care has changed in rural China. This study aims to inves-
tigate the competition relationship between drugstore and primary care in rural 
China. Methods: We collect information of treatment procedure of 1015 patients 
from 18 villages at three counties of Shandong Province in China with different eco-
nomic and geographical environment from January to May 2015 by the household 
investigation, supported by National Natural Science Foundation of China [Grant 
Number 71203124]. Competition relationship between drugstore and primary care is 
measured as growth rate of the number of drugstore and primary care. The indica-
tor of patients’ treatment choice is proportion rate of purchasing pharmaceuticals 
channel. The relationship between competition relationship and patients’ choice 
is identified by interviews with stakeholders such as the leader of County Health 
Bureau and primary care. Results: From 2010 to 2014, the number of drugstore in 
poorest and richest County has increased respectively 2.43 times and 0.18 times. 
However, the number of primary care keeps unchanged. At the same time, the treat-
ment choice of patients including village clinic(46.31%), drugstore(22.17%), county 
hospitals(7.49%), township hospitals(6.60%) and other hospitals(17.44%) . Drugstore 
has become the second biggest pharmaceuticals sale channel in rural china. The 
reason for this issue is the limit of only using essential medicines by no-profit 
sale for primary care but not for drugstore. ConClusions: Essential medicine 
policy has changed the competition relationship of pharmaceutical market in rural 
China, which affects treatment choice of patients. The treatment choice of patients 
is threatening the development of essential medicine in rural China. Keywords: 
essential medicine; competition; drugstore; primary care
HealTH caRe use & Policy sTudies – formulary development
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Brook RA1, Smeeding JE1, Sax MJ2
1The TPG-NPRT, Glastonbury, CT, USA, 2The Pharmacy Group (TPG), Glastonbury, CT, USA
objeCtives: Determine how medical and pharmacy directors (MDs+PDs) of US 
health plans, insurers, and PBMs manage specialty pharmaceuticals (SPs). In 
2014 SPs accounted for one-third of spending, up from 23% in 2009. Methods: 
Managed care (MC) MDs+PDs from public and private plans covering multiple types 
of members completed an online interactive survey of: advisor+plan information; 
use of specialty-pharmacies, and current/future coverage of SPs. Results: Fifty-
four percent of respondents were MDs, the remainder mostly pharmacists. Most 
worked for a health plan (83.6%) and the plans were: 39.6%= local; 35.4%= National; 
25.0%= regional. SP providers were restricted by 53.7% of the plans, of those with 
restrictions: the majority restrict SP provider services to a small set under contract 
(63.0%), 17.4% allow any SP; and 6.5% only restricted products available through mul-
tiple specialty-pharmacies. Plans covered clinician-administered products (injec-
tions/infusions) under the medical-benefit (MB= 67.3%); none exclusively under the 
pharmacy-benefit (PB= 0%); and 32.7% based on cost-thresholds. Most plans (72.9%) 
do not anticipate a change, 18.8% expect a change before 12-2016 and 2.1% prior to 
12-2018. Oral Biologics (OBs) were managed under the PB 78.3%; 10.9% under the 
MB; the other 10.9% based on cost-thresholds. Benefits for OBs are not expected to 
change by 71.1% of the plans, 11.1% were currently making changes; 13.3% expect 
changes prior to 12-2016; and 4.4% before 12-2018. SP and OB co-pays vary by group 
and benefit design and are shifting from fixed to percent co-pays. Responses to open 
ended questions placed SP products at the top causes for concern currently, and 
for the coming years. ConClusions: Expenditures for SP products and the use of 
specialty pharmacy will continue to grow. The environment for MC is undergoing a 
series of changes, and payor medical directors and pharmacy directors, who com-
monly serve as P&T Committee members will guide how changes to benefit and 
plan design are implemented in the future.
